Medical Supplies

Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda

Retrieved on: 
Thursday, April 4, 2024
Packaging, Logistics, Supply Chain Management, Manufacturing, Other Health, Public Relations, Investor Relations, Marketing, Communications, Medical Devices, Social Media, Small Business, Human Resources, Science, Other Transport, Professional Services, Trucking, Medical Supplies, Health, Transport, Managed Care, Other Science, General Health, Research, Rockwell Medical, The Company, AMI, Peritoneal dialysis, Senior, Dialysis, Vaccine

Rockwell Medical signed a five-year distributor agreement with BioNuclear through which BioNuclear may import, sell, promote and distribute Rockwell Medical's hemodialysis concentrates products within the Dominican Republic.

Key Points: 
  • Rockwell Medical signed a five-year distributor agreement with BioNuclear through which BioNuclear may import, sell, promote and distribute Rockwell Medical's hemodialysis concentrates products within the Dominican Republic.
  • The amended distribution agreement between Rockwell Medical and AMI expands the list of hemodialysis products that AMI is purchasing from the Company, includes purchasing commitments, and generates a profit margin consistent with Rockwell Medical's gross margin guidance for 2024.
  • "This updated distribution agreement with Rockwell Medical affords us the ability to serve and deliver more high-quality, life-sustaining products to the fragile dialysis population in Bermuda."
  • "The global reach of our hemodialysis concentrates products continues to grow," said Tim Chole , Senior Vice President, Sales and Marketing at Rockwell Medical.

Heart Rhythm Clinical and Research Solutions and the Real World Evidence Consortium Launch EVERCOOL AF Study on Attune Medical’s ensoETM®

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Surgery, Medical Supplies, Hospitals, Cardiology, Other Health, Pharmaceutical, Health, Science, Real, RWE, Atrial fibrillation, Procedural, Multimedia

Heart Rhythm Clinical and Research Solutions (HRCRS) and the Real World Evidence (RWE) Consortium have enrolled the first patient in the REView of ProcEdural FactoRs and Outcomes after Atrial Fibrillation Ablation with Active Esophageal COOLing (EVERCOOL AF) study.

Key Points: 
  • Heart Rhythm Clinical and Research Solutions (HRCRS) and the Real World Evidence (RWE) Consortium have enrolled the first patient in the REView of ProcEdural FactoRs and Outcomes after Atrial Fibrillation Ablation with Active Esophageal COOLing (EVERCOOL AF) study.
  • The study is part of a multi-center observational study evaluating the impact of proactive esophageal cooling on patient outcome, throughput, and experience in high volume centers.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240404481691/en/

Fortune Media and Great Place To Work Name Vizient to ‘100 Best Companies to Work For’ in 2024

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Pharmaceutical, Business, Medical Devices, Hospitals, Publishing, Data Analytics, Communications, Medical Supplies, Human Resources, Practice Management, Health, Consulting, HR, Culture, Organization, Growth, Face, Consultant, PEOPLE, Trust, Workplace

Great Place To Work® and Fortune magazine have recognized Vizient as one of the Fortune 100 Best Companies to Work For® in 2024.

Key Points: 
  • Great Place To Work® and Fortune magazine have recognized Vizient as one of the Fortune 100 Best Companies to Work For® in 2024.
  • Earning a spot means that Vizient is one of the best companies to work for in the country.
  • The 100 Best Companies to Work For list is the only recognition that focuses on how employees feel about their workplace.
  • Great Place To Work evaluates confidential feedback from employees, matching against HR data from participating companies.

Firefighter PPE Market Growth Opportunitiy Analysis Report 2024: Focus on Central & Eastern Europe, Russia, the Middle East, Africa, South America, and Asia - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 4, 2024
Public Policy, Government, Health, Medical Supplies, Law Enforcement, Emergency Services, Growth, Decontamination, Firefighter, Central and Eastern Europe, Particulates, CEN, PPE, NFPA, Personal protective equipment

The "Firefighter PPE Market Growth Opportunities, 2024: Central & Eastern Europe, Russia, the Middle East, Africa, South America, and Asia" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Firefighter PPE Market Growth Opportunities, 2024: Central & Eastern Europe, Russia, the Middle East, Africa, South America, and Asia" report has been added to ResearchAndMarkets.com's offering.
  • This firefighting PPE report covers all the regions except North America and Western Europe.
  • The areas include Central and Eastern Europe, Russia, the Middle East, Africa, South America, and Asia.
  • Given the lucrative growth opportunities, larger firefighting PPE manufacturers are expected to pursue M&As in the next 3 to 5 years to reduce competition and boost revenue share.

UFC® Names Hostage Tape Official Sleep Aid Partner

Retrieved on: 
Thursday, April 4, 2024
Other Health, Events, Concerts, Other Sports, Marketing, Boxing, Martial Arts, General Entertainment, Communications, Other Entertainment, TV and Radio, Sports, Fitness & Nutrition, Entertainment, Digital Marketing, Health, Medical Supplies, Exercise, MMA, UFC Performance Institute, Partnership, WWE, Sleep, Athlete, Octagon, Mouth, Multimedia, UFC, Hostage, Rehabilitation

UFC, the world’s premier mixed martial arts organization, and Hostage Tape, a leading sleep aid company, today announced a marketing partnership that will see Hostage Tape strategically activate its brand within some of UFC’s most significant assets.

Key Points: 
  • UFC, the world’s premier mixed martial arts organization, and Hostage Tape, a leading sleep aid company, today announced a marketing partnership that will see Hostage Tape strategically activate its brand within some of UFC’s most significant assets.
  • View the full release here: https://www.businesswire.com/news/home/20240404032148/en/
    Hostage Tape mouth tape is the "Official Sleep Aid of the UFC".
  • (Photo: Business Wire)
    Under the new agreement, Hostage Tape will become the Official Sleep Aid Partner of UFC with global exclusivity in several product categories, including mouth tape, nose strips, and sleep masks.
  • For a limited time, Hostage Tape is offering a UFC Hostage Tape sample pack with five nights of mouth tape & nose strips.

Johnson & Johnson Expands Commitment to Advance Health Equity

Retrieved on: 
Wednesday, April 3, 2024
Other Health, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Health Technology, Science, Biotechnology, Medical Supplies, Other Science, Health, Community, Organization, White, Health equity, Male, Empathy, Health care, Mortality, City, Spelman College, Johnson & Johnson, Hispanic and Latino Americans, National Association, Student, Nursing, J&J

Johnson & Johnson announced today that it is collaborating with more than 100 community-led health organizations supporting historically marginalized communities across the United States — building on the Company’s multiyear, multimillion-dollar efforts to improve health equity.

Key Points: 
  • Johnson & Johnson announced today that it is collaborating with more than 100 community-led health organizations supporting historically marginalized communities across the United States — building on the Company’s multiyear, multimillion-dollar efforts to improve health equity.
  • Supporting the work of grassroots organizations, community health centers and national associations is integral to identifying and implementing enduring healthcare solutions,” said Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs at Johnson & Johnson.
  • Black Women’s Health Imperative aims to empower Black women to take charge of their health through diabetes prevention and self-management classes.
  • J&J recently held a Health Equity Innovation Challenge to support innovative solutions developed by entrepreneurs and start-ups.

Experic Appoints Philip Dunne as Director, EU Operations

Retrieved on: 
Wednesday, April 3, 2024
Other Manufacturing, Other Science, Practice Management, Medical Supplies, FDA, Research, Managed Care, Packaging, General Health, Logistics, Supply Chain Management, Manufacturing, Other Health, Pharmaceutical, Medical Devices, Clinical Trials, Transport, Biotechnology, Health, Science, Philip, GMP, Knowledge, CDMO, Clinical trial, GDP, Vaccine

Experic , a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, today announced the appointment of Philip Dunne as Director of EU Operations, to head up initial operations of its recently announced 10,000 sq.

Key Points: 
  • Experic , a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, today announced the appointment of Philip Dunne as Director of EU Operations, to head up initial operations of its recently announced 10,000 sq.
  • "We are delighted to have Philip on board to support our recent EU expansion," said Vice President of Operations, Brian Fagan.
  • "A seasoned industry professional, he brings a diversified skill set in pharmaceutical and medical device clinical trial supply services to the Experic team.
  • "I am very excited to be joining the Experic team to bring their first international facility online," shared Philip Dunne, Director of EU Operations.

InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K

Retrieved on: 
Wednesday, April 3, 2024
Medical Supplies, Medical Devices, Health, Practice Management, Other Health, General Health, Exchange, The, Classification, Security (finance), ASC, Annual report, File, Accounting, Delinquent, Medical device

In accordance with Section 1007 of the Company Guide, the Company will have six months from the date of the Filing Delinquency (the "Initial Cure Period"), to file the Delinquent Report with the SEC.

Key Points: 
  • In accordance with Section 1007 of the Company Guide, the Company will have six months from the date of the Filing Delinquency (the "Initial Cure Period"), to file the Delinquent Report with the SEC.
  • The Exchange will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured.
  • If the Company fails to file the Delinquent Report during the Initial Cure Period, the Exchange may, in its sole discretion, grant an up to six-month additional cure period (the "Additional Cure Period").
  • There can be no assurance that the Company will ultimately regain compliance with all applicable Exchange listing standards.

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Biotechnology, FDA, Health, Pharmaceutical, Optical, Health Technology, Medical Devices, Hospitals, Surgery, Clinical Trials, Catalent, Series, Absorption, Midazolam, Ketamine, Medication

Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019.

Key Points: 
  • Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019.
  • The capital raised will primarily support the further development of MELT-300, including the MELT-300 Phase 3 program.
  • “With this round of financing, we’ve obtained the funding to further the development of MELT-300, including conducting our recently commenced Phase 3 program.
  • Their shared belief in the vision of MELT-300 and their confidence in its potential to revolutionize short-duration procedural sedation is incredibly valuable to us.”
    Newbridge Securities Corporation acted as the exclusive placement agent for the Series B Preferred Stock Offering.

Johnson & Johnson to Participate in the BofA Securities Health Care Conference

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Medical Devices, Health, Health Technology, Pharmaceutical, Biotechnology, Webcast, Conference, JNJ, Eastern Time Zone, Encore, Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada.
  • John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time).
  • The audio webcast replay will be available approximately 48-hrs after the webcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240402572248/en/